EMJ Neurology 13 [Supplement 1] . 2025

In this issue

Great advances have been made in the field of generalised myasthenia gravis (gMG) in recent years; however, many patients remain dissatisfied with their disease state despite being on treatment. This insightful interview explores the growing consensus among specialists that minimising symptom burden is the best way to improve outcomes, with key opinion leaders Carlos Casasnovas, Kristl Claeys, and John Vissing sharing their expert knowledge on the past, present, and future of gMG management.